Journal of Urologic Oncology

Editorial

November 30, 2023

Summarizing the Intentions and Outcomes of JUO 2023 Issue 3

Cheol Kwak

J Urol Oncol. 2023;21(3):181-182.

Invited Review

November 30, 2023

Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma

Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.

J Urol Oncol. 2023;21(3):183-199.

The purpose of this review is to provide an up-to-date understanding of the literature describing the impact of body composition on renal cell carcinoma (RCC) prognosis and outcomes. Although obesity...

Topic Article

November 30, 2023

Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis

Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.

J Urol Oncol. 2023;21(3):200-207.

Purpose: This study investigated the effects of preoperative renal artery embolization (PRAE) before radical nephrectomy (RN) for advanced nonmetastatic renal cell carcinoma (RCC) on perioperative and oncologic outcomes. Materials and Methods:...

Invited Review

November 30, 2023

The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects

Hyerim Ha, Joo Han Lim

J Urol Oncol. 2023;21(3):208-216.

Renal cell carcinoma (RCC) remains a significant challenge in oncology, prompting thorough investigations into adjuvant treatments aimed at enhancing both survival and quality of life for patients. In this review,...

Invited Review

November 30, 2023

Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type

Chan Woo Wee, Jaeho Cho

J Urol Oncol. 2023;21(3):217-227.

Renal cell carcinoma (RCC) has traditionally been considered one of the most radioresistant tumors based on in vitro and clinical studies that utilized a low biologically effective dose. However, recent...

Invited Review

November 30, 2023

Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023

Jiwoong Yu, Hyun Hwan Sung

J Urol Oncol. 2023;21(3):228-240.

Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) poses a significant clinical challenge, prompting a need for effective treatment options. Although radical cystectomy is a standard approach, it is burdened by...

Topic Article

November 30, 2023

Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer

Chung Un Lee, Wan Song, Minyong Kang, et al.

J Urol Oncol. 2023;21(3):241-248.

Purpose: Radical cystectomy (RC) is recommended for patients with non–muscle-invasive bladder cancer (NMIBC) who are unresponsive to intravesical bacillus Calmette-Guérin (BCG) instillation. However, RC is a very risky treatment, and...

Original Article

November 30, 2023

Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy

Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.

J Urol Oncol. 2023;21(3):249-256.

Purpose: The efficacy of standard chemotherapy or radical cystectomy in patients who have urothelial tumors with variant histology (VH) is very limited in terms of their prognosis. This study aimed...

Topic Article

November 30, 2023

Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.

J Urol Oncol. 2023;21(3):257-263.

Purpose: This study aimed to identify predictive factors for the response to abiraterone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Materials and Methods: This study analyzed the clinical characteristics...

Topic Article

November 30, 2023

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy

Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.

J Urol Oncol. 2023;21(3):264-270.

Purpose: In present, the use of androgen receptor targeting agents (ARTA) is one of the standard treatments for metastatic castration-resistant prostate cancer (mCRPC) without previous chemotherapy. However, some patients may...

Original Article

November 30, 2023

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel

Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.

J Urol Oncol. 2023;21(3):271-276.

Purpose: We propose a new potential marker of progression-free survival (PFS) called negative delta-prostate-specific antigen (PSA) time ratio (NDPSATR) and compare it with conventional PSA response, defined as PSA decline...

Erratum: Addition of the second author

November 30, 2023

Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer

Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al.

J Urol Oncol. 2023;21(3):277-277.

Current Issue: Volume 21(3); Nov 2023

This archive contains links to the full-text of all issues.

Current issue

Volume 21(3); November

All issues

Vol. 21
2023

v.21(1) Mar 2023

v.21(2) Jul 2023

v.21(3) Nov 2023

The Korean Journal of Urological Oncology2003 (v1 n1) to 2022 (v22 n4)

Vol. 20
2022

v.20(1) Feb 2022

v.20(2) May 2022

v.20(3) Aug 2022

v.20(4) Nov 2022

Vol. 19
2021

v.19(1) Feb 2021

v.19(2) May 2021

v.19(3) Aug 2021

v.19(4) Nov 2021

Vol. 18
2020

v.18(1) Apr 2020

v.18(2) Aug 2020

v.18(3) Dec 2020

Vol. 17
2019

v.17(1) Apr 2019

v.17(2) Aug 2019

v.17(3) Dec 2019

Vol. 16
2018

v.16(1) Apr 2018

v.16(2) Aug 2018

v.16(3) Dec 2018

Vol. 15
2017

v.15(1) Apr 2017

v.15(2) Aug 2017

v.15(3) Dec 2017

Vol. 14
2016

v.14(1) Apr 2016

v.14(2) Aug 2016

v.14(3) Dec 2016

Vol. 13
2015

v.13(1) Apr 2015

v.13(2) Aug 2015

v.13(3) Dec 2015

Vol. 12
2014

v.12(1) Apr 2014

v.12(2) Aug 2014

v.12(3) Dec 2014

Vol. 11
2013

v.11(1) Apr 2013

v.11(2) Aug 2013

v.11(3) Dec 2013

Vol. 10
2012

v.10(1) Apr 2012

v.10(2) Aug 2012

v.10(3) Dec 2012

Vol. 9
2011

v.9(1) Apr 2011

v.9(2) Aug 2011

v.9(3) Dec 2011

Vol. 8
2010

v.8(1) Apr 2010

v.8(2) Aug 2010

v.8(3) Dec 2010

Vol. 7
2009

v.7(1) Apr 2009

v.7(2) Aug 2009

v.7(3) Dec 2009

Vol. 6
2008

v.6(1) Apr 2008

v.6(2) Aug 2008

v.6(3) Dec 2008

Vol. 5
2007

v.5(1) Apr 2007

v.5(2) Aug 2007

v.5(3) Dec 2007

Vol. 4
2006

v.4(1) Jun 2006

v.4(2) Dec 2006

Vol. 3
2005

v.3(1) Jun 2005

v.3(2) Dec 2005

Vol. 2
2004

v.2(1) Mar 2004

v.2(2) Jun 2004

v.2(3) Sep 2004

v.2(4) Dec 2004

Vol. 1
2003

v.1(1) Mar 2003

v.1(2) Jun 2003

v.1(3) Sep 2003

v.1(4) Dec 2003

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

4,313	Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer
4,173	Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer
4,009	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
3,980	Expert Group Consensus Opinion on Prostate Cancer Diagnosis and Management in India: Part 2 of 2
3,941	Laparoscopic Radical Cystectomy With Intracorporeal Orthotopic Neobladder Reconstruction: An Initial Experience of Modified Studer Reconstruction Techniques

Cited By 2	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 2	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Cited By 1	Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer
Cited By 1	The Effects of Recombinant Bacillus Calmette-Guérin Resistant to Antimicrobial Peptides on Orthotopic Bladder Cancer Mouse Model